# A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

> **NCT03728933** · PHASE3 · TERMINATED · sponsor: **UCB Biopharma SRL** · enrollment: 23 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Rotigotine 1 milligram/24 hours
- **DRUG:** Rotigotine 2 milligram/24 hours
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03728933
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-20
- **Primary completion:** 2022-07-25
- **Final completion:** 2022-07-25
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Sponsor decision; Not a safety decision
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03728933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03728933, "A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03728933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*